Hepatocyte‐induced CD4+ T cell alloresponse is associated with major histocompatibility complex class II up‐regulation on hepatocytes and suppressible by regulatory T cells

Daphne E. DeTemple, Felix Oldhafer, Christine S. Falk, Chen Chen‐Wacker, Constanca Figueiredo, Moritz Kleine, Wolf Ramackers, Kai Timrott, Frank Lehner, Juergen Klempnauer, Michael Bock, Florian W. R. Vondran – 24 January 2018 – Hepatocyte transplantation is a promising therapeutic approach for various liver diseases. Despite the liver's tolerogenic potential, early immune‐mediated loss of transplanted cells is observed, and longterm acceptance has not been achieved yet.

Intraregional model for end‐stage liver disease score variation in liver transplantation: Disparity in our own backyard

Kristopher P. Croome, David D. Lee, Justin M. Burns, Andrew P. Keaveny, C. Burcin Taner – 24 January 2018 – Variation in average Model for End‐Stage Liver Disease (MELD) score at liver transplantation (LT) by United Network for Organ Sharing (UNOS) regions is well documented. The present study aimed to investigate MELD variation at the interregional, intraregional, and intra–donation service area (DSA) levels. Patients undergoing LT between 2015 and 2016 were obtained from the UNOS standard analysis and research file.

Bile acids stimulate cholangiocyte fluid secretion by activation of transmembrane member 16A Cl− channels

Qin Li, Amal Dutta, Charles Kresge, Abhijit Bugde, Andrew P. Feranchak – 23 January 2018 – Bile acids stimulate a bicarbonate‐rich choleresis, in part, through effects on cholangiocytes. Because Cl− channels in the apical membrane of cholangiocytes provide the driving force for secretion and transmembrane member 16A (TMEM16A) has been identified as the Ca2+‐activated Cl− channel in the apical membrane of cholangiocytes, the aim of the present study was to determine whether TMEM16A is the target of bile‐acid–stimulated Cl− secretion and to identify the regulatory pathway involved.

cHCC‐CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation

Elizabeth Brunt, Shinichi Aishima, Pierre‐Alain Clavien, Kathryn Fowler, Zachary Goodman, Gregory Gores, Annette Gouw, Alex Kagen, David Klimstra, Mina Komuta, Fukuo Kondo, Rebecca Miksad, Masayuki Nakano, Yasuni Nakanuma, Irene Ng, Valerie Paradis, Young Nyun Park, Alberto Quaglia, Massimo Roncalli, Tania Roskams, Michiie Sakamoto, Romil Saxena, Christine Sempoux, Claude Sirlin, Ashley Stueck, Swan Thung, W.M.S.

Hepatic stellate cell–derived platelet‐derived growth factor receptor‐alpha‐enriched extracellular vesicles promote liver fibrosis in mice through SHP2

Enis Kostallari, Petra Hirsova, Alena Prasnicka, Vikas K. Verma, Usman Yaqoob, Nicha Wongjarupong, Lewis R. Roberts, Vijay H. Shah – 23 January 2018 – Liver fibrosis is characterized by the activation and migration of hepatic stellate cells (HSCs), followed by matrix deposition. Recently, several studies have shown the importance of extracellular vesicles (EVs) derived from liver cells, such as hepatocytes and endothelial cells, in liver pathobiology.

Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

Rachel J. Church, Gerd A. Kullak‐Ublick, Jiri Aubrecht, Herbert L. Bonkovsky, Naga Chalasani, Robert J. Fontana, Jens C. Goepfert, Frances Hackman, Nicholas M. P. King, Simon Kirby, Patrick Kirby, John Marcinak, Sif Ormarsdottir, Shelli J. Schomaker, Ina Schuppe‐Koistinen, Francis Wolenski, Nadir Arber, Michael Merz, John‐Michael Sauer, Raul J. Andrade, Florian van Bömmel, Thierry Poynard, Paul B. Watkins – 22 January 2018 – Current blood biomarkers are suboptimal in detecting drug‐induced liver injury (DILI) and predicting its outcome.

Subscribe to